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HIV-1its of antigenic reactivity and epitope accessibility of the V3 domain of primary
HIV-1 isolates, we evaluated three human anti-V3 monoclonal antibodies (mAbs) and selected guinea pig
vaccine sera for neutralization against reference panels of subtype B and C pseudoviruses derived from early
stage infections. The mAbs and vaccine sera potently neutralized several prototype viruses, but displayed
substantially less neutralization of most reference strains. In the presence of soluble CD4 (sCD4), the breadth
of V3-mediated neutralization was increased; up to 80% and 77% of the subtype B and C viruses respectively
were sensitive to V3-mediated neutralization. Unlike sCD4, the reaction of CD4-binding site mAbs b12 and
F105 with native virus did not lead to full exposure of the V3 domain. These ﬁndings conﬁrm that V3
antibodies recognize most primary viral strains, but that the epitope often has limited accessibility in the
context of native envelope spike.
Published by Elsevier Inc.IntroductionThe trimeric HIV-1 Env spike is composed of the surface unit gp120
and transmembrane gp41 glycoproteins. Viral entry into susceptible
cells is mediated by the interaction of gp120 with the cell surface
receptor CD4, leading to conformational changes that form and expose
the co-receptor binding region of gp120 (Kwong et al., 1998;
Salzwedel et al., 2000; Wyatt and Sodroski, 1998; Xiang et al., 2002).
The V3 region of gp120 is critical for co-receptor recognition and
determines which co-receptor, CCR5 or CXCR4, is used for viral entry
(Cormier and Dragic, 2002; Huang et al., 2005; Suphaphiphat et al.,
2003). Hence, while relatively variable in linear sequence, the V3
region has some level of functional and structural conservation
(Cardozo et al., 2007; Haynes and Monteﬁori, 2006; Huang et al.,
2005; Rosen et al., 2005; Sharon et al., 2003).
During HIV-1 infection, antibodies to the V3 loop are common
(Broliden et al., 1992; Gorny et al., 2006; Haynes andMonteﬁori, 2006;
Krachmarov et al., 2001; Kraft et al., 2007; Pantophlet and Burton,
2006; Profy et al., 1990; Schreiber et al., 1994; Spenlehauer et al., 1998;
Wu et al., 1995; Zolla-Pazner, 2004). However, the V3 region appears
to play a limited role in the neutralization of most primary virus
isolates (Binley et al., 2004; Burton et al., 2004; Lusso et al., 2005;
Stamatos et al., 1998; Vancott et al., 1995). Early vaccine studies using
V3 peptides as immunogens showed a highly type-speciﬁc neutraliz-nc.ing antibody (NAb) response to V3 (Javaherian et al., 1990), whilemore
recent studies of V3 mAbs and immune sera suggest that the V3 NAb
response can be more broadly reactive (Derby et al., 2007; Haynes et
al., 2006; Moore et al., 1995b; Wu et al., 2006; Yang et al., 2004; Zolla-
Pazner, 2005). Human anti-V3 mAbs from both subtype B and non-
subtype B infected individuals can neutralize a subset of subtype B and
non-subtype B primary virus strains. Interestingly, the breadth and
potency of this neutralizations is maximized when the V3 region is
built into an unmasked V3 sensitive Env such as on virus SF162 (Binley
et al., 2004; Gorny et al., 2006; Krachmarov et al., 2006; Li et al., 2005;
Moore et al., 1995a; Pantophlet et al., 2007; Patel, Hoffman, and
Swanstrom, 2008; Zolla-Pazner et al., 2008). These data, along with
recently described atomic level structures of V3 mAb liganded to
cognate peptides, conﬁrm that there are conserved motifs within the
V3 region (Cardozo et al., 2007; Huang et al., 2005; Sharon et al., 2003;
Stanﬁeld et al., 2004; Stanﬁeld et al., 2006).
These ﬁndings are consistent with our understanding that the V3
region is displayed to varying degrees in the context of the quaternary
structure of the native viral spike of individual strains of HIV-1.
However after binding to the CD4 receptor, conformational changes in
Env result in exposure of speciﬁc regions previously inaccessible to
antibody. CD4 binding signiﬁcantly enhances gp120 binding by mAb
17b, which recognizes the co-receptor binding site (Decker et al.,
2005; Hoffman et al., 1999; Salzwedel et al., 2000; Sullivan et al.,
1998a, 1998b; Xiang et al., 2002). Similarly, the V3 loop appears to be
accessible to antibody when gp120 is in a CD4-bound state
(Krachmarov et al., 2006; Lusso et al., 2005; Mbah et al., 2001; Potts
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limited breadth of neutralization by recently isolated broadly reactive
V3mAbs, and by V3-directed vaccine sera, may be due to poor epitope
accessibility rather than antigenic diversity of the V3 region (Bou-
Habib et al., 1994; Krachmarov et al., 2005; Stamatos et al., 1998;
Vancott et al., 1995).
To study the breadth and potency of anti-V3 virus neutralization,
we used recently established reference panels of 12 acute subtype B
and 12 acute subtype C Env-pseudoviruses (Li et al., 2005; Li et al.,
2006). We evaluated three well-characterized anti-V3 mAbs and ﬁve
guinea pig (GP) vaccine-induced immune sera known to contain high
levels of anti-V3 antibodies. The mAbs and immune serawere assayed
in the presence of varying concentrations of sCD4 to test if the resulting
conformational change in Env would lead to exposure and recognition
of the V3 loop. One anti-V3 mAb, 447-52D, is known to react with the
GPGR sequence at the tip of the V3 loop which is conserved among
most subtype B isolates (Gorny et al., 1992; Zolla-Pazner et al., 2004).
The other twomAbs, 2219 and 3074, were derived from subtype B and
the circulating recombinant form (CRF) 02_AG infected individuals
respectively, and were selected for their broad proﬁle of V3 reactivity
(Gorny et al., 2002; Gorny et al., 2006; Krachmarov et al., 2005;
Krachmarov et al., 2006). The GP vaccine sera were the result of
plasmid DNA prime, recombinant adenoviruses serotype-5 (rAd5)
boost immunization with Env constructs containing a deletion of the
V1V2 loop and two small deletions on both arms of the V3 stem. This
immunization strategy produced high V3-directed NAb responses
(Chakrabarti et al., 2002; Chakrabarti et al., 2005;Wu et al., 2006; Yang
et al., 2004). Two GPs were immunized with a subtype B immunogen
and three were immunized with a subtype C immunogen.
Results
SCD4 enhances neutralization by V3-directed mAbs
We tested the subtype B-derived anti-V3 mAbs 447-52D and 2219
and the CRF02_AG-derivedmAb 3074 against subtype B viruses SF162,
BaL.26, ADA, JRFL and YU2. All three mAbs neutralized SF162 and
BaL.26 by N90% at 10 μg/ml (data not shown), but displayed more
variable activity against ADA, JRFL and YU2 (Table 1). Of interest, all
three mAbs displayed less than 50% neutralizing activity against JRFL
even though this virus contains an identical V3 amino acid sequence toTable 1
Neutralization by the indicated anti-V3 mAbs and GP vaccine sera against subtype B viruse
sCD4 IC80 μg/ml 447-52D 10 μg/ml 2219 10 μg/ml
−sCD4 +sCD4 −sCD4 +sCD4
JRFL 7.2 36% 99% 32% 98%
ADA 1.7 72% 82% 62% 78%
YU2 1.4 2% 73% 0% 64%
6535.3 8.6 87% 93% 93% 93%
QH0692.42 6.4 27% 51% 28% 45%
SC422661.8 125.3 0% 16% 18% 25%
PVO.4 46.0 4% 43% 35% 63%
TRO.11 N200 50% 48% 31% 37%
AC10.0.29 80.9 8% 39% 47% 57%
RHPA4259.7 21.6 36% 34% 29% 37%
THRO4156.18 3.1 25% 0% 14% 12%
REJO4541.67 22.5 31% 21% 47% 74%
TRJO4551.58 17.7 0% 86% 0% 83%
WITO4160.33 50.0 40% 76% 15% 67%
CAAN5342.A2 95.2 30% 26% 39% 26%
Breadth 2(13%) 7(47%) 2(13%) 9(60%
P-value 0.0625 0.016
Values indicate percent neutralization when no sCD4 was present in the assay (-sCD4) and w
later value is the percent adjusted neutralization and indicates the effect of the mAb or GP se
the concentration of sCD4 required to inhibit viral entry by 80%. Note that the IC80 for sCD4 w
mAb or GP sera was calculated using viral entry values at this level of sCD4 (e.g., Fig. 3). Va
breadth of neutralization. P-values were computed using the two-sided McNemar's test.BaL.26 (Supplementary Fig. 1). However, pre-incubation with sCD4
substantially increased the sensitivity of JRFL, ADA and YU2 to neutra-
lization by each of the V3 mAbs. In our luciferase-based pseudovirus
neutralization assay, viral entry is quantiﬁed by relative light units
(RLU) and neutralization is calculated as the percent reduction in
virus entry caused by antibody compared to baseline viral entry with
no antibody present (Fig. 1A). To account for the effect on virus entry
by sCD4, antibody-mediated neutralization was calculated using a
baseline of viral entry that occurred with the relevant concentration
of sCD4 present. Adjusted neutralization (Fig. 1B) depicts the V3
mAb-mediated neutralization that occurred with various concentra-
tions of sCD4 present. As sCD4 concentration increased from zero to
5 μg/ml, 447-52D adjusted neutralization of JRFL increased from 38%
to 95%. In these experiments, the mAb was used at a ﬁxed concen-
tration of 10 μg/ml. A similar pattern of JRFL neutralization was
observed for mAbs 2219 and 3074 (Fig. 1C). Hence, the weak JRFL
neutralization by these V3 mAbs was not due to poor antigenic
recognition of the JRFL V3 region, but rather due to limited accessi-
bility of the epitope. SCD4 also enhanced the V3 mAb neutralization
of ADA and YU2 (Figs. 1D and 1E). Note that the CRF02_AG-derived
mAb 3074 was able to neutralize subtype B viruses JRFL and ADA
when sCD4 was present, though not as potently as the two subtype
B-derived mAbs. Interestingly, mAb 17b neutralization was only mo-
destly increased in the presence of sCD4, and was never above 50%
against JRFL, ADA and YU2 (Figs. 1C, 1D and 1E). This suggests that
while the level of sCD4 used in these experiments was enough to
inhibit viral entry by 50%–80%, and was enough to expose the V3
region, it was insufﬁcient to result in full conformational exposure of
the co-receptor binding site. The experiments described above were
performed with varying concentrations of sCD4 and a ﬁxed concen-
tration of the V3 mAbs. We also determined the effect of a ﬁxed
concentration of sCD4 on the potency of mAb 447-52D. The neutra-
lization IC50 for 447-52D decreased from N10 μg/ml in the absence of
sCD4 to 0.67 μg/ml and 0.025 μg/ml in the presence of 1 and 5 μg/ml
of sCD4 respectively, a greater than 400-fold increase in mAb
neutralization potency (Fig. 1F).
SCD4 enhances and broadens neutralization by GP vaccine sera
We previously demonstrated that DNA prime, rAd5 boost immu-
nization with Env constructs containing a deletion of the V1V2 loops with and without sCD4 present
3074 10 μg/ml 82-2 1:10 82-4 1:10
−sCD4 +sCD4 −sCD4 +sCD4 −sCD4 +sCD4
0% 94% 29% 100% 31% 97%
63% 69% 55% 73% 58% 67%
25% 41% 9% 97% 29% 40%
24% 74% 17% 85% 4% 16%
68% 73% 46% 66% 12% 47%
18% 18% 41% 0% 37% 22%
39% 57% 56% 90% 44% 71%
29% 13% 70% 75% 66% 67%
13% 12% 59% 80% 13% 55%
34% 45% 15% 12% 9% 11%
10% 8% 38% 39% 23% 21%
29% 55% 34% 78% 6% 41%
5% 65% 0% 87% 14% 73%
12% 41% 31% 68% 34% 55%
32% 17% 46% 67% 34% 59%
) 2(13%) 7(47%) 4(27%) 12(80%) 2(13%) 8(53%)
0.0625 0.008 0.031
ith sCD4 present (+sCD4) at a concentration sufﬁcient to inhibit viral entry by 80%. The
ra calculated based on baseline viral entry with sCD4 present. The second column shows
as derived separately for each virus and the percent adjusted neutralizationmediated by
lues greater than 50% neutralization are shown in bold and were used to calculate the
Fig.1. Effect of sCD4 on neutralization of JRFL, ADA and YU2 by anti-V3mAbs 447-52D, 2219, 3074 and anti-co-receptormAb 17b. (A) Viral entry expressed as luciferase (RLU) of JRFL is
shownwith varying concentrations of sCD4. Black bar shows viral entry with no mAb and no sCD4 present. Grey bar shows viral entry with 447-52D. White bars show the effect of
sCD4 alone on viral entry. Hatched bars show the effect of each concentration of sCD4 with a ﬁxed amount (10 μg/ml) of mAb 447-52D. (B) The percent adjusted neutralization was
calculated from (A) using RLU values for each concentration of sCD4 as the baseline for viral entry. The additional effect on viral entry by 10 μg/ml of mAb 447-52D is the percent
adjusted neutralization. (C), (D) and (E) show the percent adjusted neutralization by several mAbs against viruses JRFL, ADA and YU2. Legend in (C) applies to (D) and (E). (F) Serial
dilutions of mAb 447-52D alone, or with a ﬁxed concentration of sCD4were tested to calculate the impact of sCD4 on the potency of mAb 447-52D neutralization. Note that for graphs
C, D and E, the IC50 and IC80 effect of sCD4 against each virus are indicated on the X-axis.
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V3-directed NAb responses (Chakrabarti et al., 2002; Chakrabarti et al.,
2005; Wu et al., 2006; Yang et al., 2004). In the present study, we
examined two such GP sera from animals immunized with an HIV-1
subtype B-based Env immunogen. GP sera 82-2 and 82-4 had high and
moderate NAb levels respectively (Supplementary Fig. 2). Virus
neutralization by both sera was largely mediated by antibodies to
the V3 loop, as shown by peptide competition studies (Wu et al.,
2006).
As we previously described, these sera displayed little neutraliza-
tion of viruses JRFL, ADA and YU2. However, in the presence of sCD4, a
1:10 dilution of the sera neutralized all three viruses (Fig. 2A). To assess
the increase in potency of the sera caused by sCD4, the sera were
serially diluted in the presence of 1 μg/ml or 5 μg/ml of sCD4 (Fig. 2B).
The neutralization IC50 of serum 82-2 against JRFL improved from 1:12
in the absence of sCD4 to 1:100 and N1:1,000 in the presence of 1 and
5 μg/ml of sCD4, respectively. Similarly, the neutralization IC50 of 82-4
increased from b1:10 in the absence of sCD4 to 1:30 and 1:625 in the
presence of 1 and 5 μg/ml of sCD4, respectively. The V3 speciﬁcity of
these neutralization activities was conﬁrmed by peptide competition
assays using a V3 peptide that matched the immunogen V3 sequence
(Fig. 2C).
To understand the potential breadth of reactivity of these V3 mAbs
and V3-directed GP vaccine sera, we extended this analysis to a
recently described reference panel of 12 acute subtype B viruses (Li et
al., 2005). The neutralization proﬁles of three mAbs and two GP sera
against four selected viruses are graphically shown in Fig. 3. These fourviruses demonstrate the spectrum of V3 neutralization observed
among the subtype B reference viruses. Virus 6535.3 was highly
sensitive to V3-mediated neutralization by two mAbs without sCD4
present, but displayed increased sensitivity to mAb 3074 and GP 82-2
serum after sCD4 was added; virus WITO4160.33 became generally
sensitive to mAb and serum V3-mediated neutralization after sCD4
was added to the assay; virus CAAN5342.A2 became sensitive to the
GP sera, but not themAbs and virus THRO4156.18was resistant to both
anti-V3 mAbs and GP sera, even after sCD4 was added. Note that the
concentration of sCD4 required to inhibit 50% or 80% viral entry, and
hence to expose the V3 loop to antibody, varied among viruses (Fig. 3
and Table 1). As summarized in Table 1, the anti-V3 mAbs at 10 μg/ml,
and the GP vaccine sera at a 1:10 dilution, displayed limited
neutralization breadth among the 15 viruses tested. It should be
noted that this panel of 15 pseudoviruses, which includes JRFL, ADA,
YU2 and 12 reference strains, was chosen to exclude viruses such as
BaL.26 and SF162 that are highly sensitive to V3-mediated neutraliza-
tion. We used a value of 50% virus neutralization by 10 μg/ml of mAb,
or a 1:10 serum dilution, as measure of positive virus neutralization.
Our prior published data suggests that a GP vaccine serum neutra-
lization value of 50% or greater is a readily reproducible measure of
antibody-mediated virus neutralization (Shu et al., 2007; Wu et al.,
2006; Yang et al., 2004). By this measure, the three mAbs and two GP
sera neutralized two to four of the 15 viruses (13–27%). In the presence
of sCD4, themAbs and GP sera both displayed increased neutralization
breadth. For example, mAb 2219 neutralized two of 15 viruses without
sCD4 and nine of 15 viruses in the presence of sCD4, and serum 82-2
Fig. 2. Neutralization by GP vaccine sera. (A) The effect of sCD4 on neutralization by GP sera 82-2 and 82-4. Pre-immune and vaccine sera are shown by open and ﬁlled symbols
respectively. The IC50 and IC80 of sCD4 against each virus are indicated on the X-axis. (B) Serial dilutions of GP vaccine sera alone, or with a ﬁxed concentration of sCD4 were tested to
calculate the impact of sCD4 on the potency of serum neutralization. (C) With 5 μg/ml of sCD4 present, GP vaccine sera neutralize JRFL predominantly via anti-V3 antibodies. A V3
peptide (30 μg/ml) matched to the vaccine immunogen was used to inhibit the V3 mediated neutralization by GP vaccine sera. A scrambled V3 peptide had no inhibitory effect (not
shown).
288 X. Wu et al. / Virology 380 (2008) 285–295neutralization increased from four to 12 of 15 viruses. Hence, up to
80% of the subtype B viruses tested were sensitive to V3-mediated
neutralization when sCD4 was present. This increase in breadth was
statistically signiﬁcant for mAb 2219 and for both GP sera (Table 1).
Statistical analysis comparing the percent neutralization by each mAb
and serum against all 15 viruses, with and without sCD4, was also
performed. The inclusion of sCD4 in the assay resulted in a statistically
signiﬁcant increase in the median neutralization values for all three
anti-V3 mAbs and both GP vaccine sera, but not for mAb 17b
(Supplementary Fig. 3).
SCD4 broadens neutralization of V3-directed mAbs and subtype C GP
vaccine sera against a reference panel of subtype C viruses
We further evaluated the effect of sCD4 on neutralization of a
standardized panel of 12 subtype C reference viruses (Li et al., 2006).We used the same three mAbs, including the CRF02_AG-derived 3074,
and included sera from three selected GPs that received a subtype C
Env immunogen. The subtype C Env immunogen was similar to the
subtype B immunogen except that the V3 region was replaced with a
subtype C V3 sequence (Wu et al., 2006). All three GP sera neutralized
V3 sensitive subtype C viruses (Supplementary Fig. 2) and hadmodest
to high levels of anti-V3 NAbs (Wu et al., 2006). The neutralization
proﬁles of ﬁve selected subtype C viruses are graphically shown in Fig.
4. TV1.29 was chosen because it was previously shown to be sensitive
to V3 neutralization by subtype C GP vaccine sera (Wu et al., 2006);
the other four viruses demonstrate the spectrum of V3 neutralization
observed among the subtype C reference viruses. The anti-V3 mAbs
displayed little neutralization of the subtype C reference viruses, but
the presence of sCD4 resulted in mAb neutralization of some viruses
such as ZM233M.PB6 and CAP210.2.00.E8 (Fig. 4). The GP vaccine sera
displayed neutralization of some subtype C viruses without sCD4
Fig. 3. The effect of sCD4 on V3-mediated neutralization of four selected subtype B reference viruses. Data for anti-V3 mAbs and subtype B GP vaccine sera are shown against each
virus. The IC50 and IC80 of sCD4 against each virus are indicated on the X-axes. Note that the scale of the X-axes differs among viruses.
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increased by adding sCD4 to the assay (Fig. 4). Using the same 50%
value to denote positive virus neutralization, mAb 3074 neutralization
increased from two to ﬁve of 13 viruses when sCD4 was present and
GP serum 86-6 neutralization increased from ﬁve to ten of 13 viruses
(Table 2). While these increases in neutralization breadth were not
statistically signiﬁcant (Table 2), comparisons of median percent
neutralization values with and without sCD4 indicate signiﬁcant
increases in potency for mAbs 2219, 3074 and GP serum 86-6
(Supplementary Fig. 4). We veriﬁed the speciﬁcity of the neutraliza-
tion by GP sera 83-2, 86-2 and 86-6 against virus TV1.29 by V3 peptide
competition (Fig. 5). The presence of 5 μg/ml of sCD4 markedly
increased the neutralization titers of all three immune sera against
TV1.29, and this was inhibited by 30 μg/ml of a V3 peptide that
matched the V3 immunogen sequence. These data indicate that
similar to subtype B viruses, the subtype C V3 region is recognized by
known V3 mAbs and by immune sera, but is poorly accessible to
antibody on the functional virion.
Approximately 25% of pseudoviruses in the subtype B and C panels
we tested remained resistant to V3-antibody neutralization, even in
the presence of sCD4 at IC80 or higher concentrations. The explanation
of this observation could be that sCD4 did not trigger exposure of V3
loop or that antigenic variation resulted in lack of recognition by any of
the antibody reagents tested. This could be partially addressed by
testing antibody reactivity to the solublemonomeric g120 captured on
an ELISA plate. Of the three subtype B viruses that were resistant to
V3-mediated neutralization, the gp120 of SC422661.8 and
RHPA4259.7 was strongly bound by mAb 447-52D (data not shown).
This suggests that this neutralization resistance was due to a lack of
exposure of the V3 loop on the native virus. In contrast, the gp120
from virus THRO4156.18, which has an unusual GPGG sequence at the
tip of the V3 loop, did not react with 447-52D. Hence, bothmechanisms may be occurring; the masked V3 loop of some viruses
are not readily exposed, even when high concentrations of sCD4 are
present and amino acid sequence variation may account for the
neutralization resistance of other viruses. Although V1V2 length and
positioning of glycosylation have been suggested as major factors in
masking the V3 epitope (Krachmarov et al., 2006), we did not ﬁnd
signiﬁcant differences in the length of V1V2 or number of potential N-
linked glycosylation sites between viruses that were sensitive to anti-
V3 antibodies and those that were resistant.
Anti-CD4-binding site (CD4bs) mAbs b12 and F105 did not affect
V3-mediated neutralization
In the hope of ﬁnding an antibody that would bind to the CD4bs of
HIV-1 Env and induce conformational changes similar to those
induced by sCD4, we tested the anti-CD4bs mAbs b12 and F105 for
their effect on neutralization of V3-directed mAb and GP immune
serum. Although the presence of sCD4 increased neutralization of JRFL
by 447-52D and immune serum 82-4, the presence of b12 and F105 at
concentrations sufﬁcient to inhibit JRFL entry by greater than 50% did
not induce V3 mediated neutralization (Fig. 6). Similar results were
obtained with virus YU2 (data not shown). These data suggest that
mAbs b12 and F105 do not induce a conformation alteration in Env
that exposes the V3 loop to NAbs.
Discussion
The V3 region of HIV-1 has been considered a potential vaccine
target because of its immuno-dominance in eliciting antibody
responses. Anti-V3 antibodies are common during natural infection
and are readily elicited by numerous peptide- or Env-based vaccine
immunogens (Broliden et al., 1992; Javaherian et al., 1990; Krachma-
Fig. 4. The effect of sCD4 on V3-mediated neutralization of TV1.29 and four selected subtype C reference viruses. Data for anti-V3 mAbs and subtype C GP vaccine sera are shown
against each virus. The IC50 and IC80 of sCD4 against each virus are indicated on the X-axes. Note that the scale of the X-axes differs among viruses.
290 X. Wu et al. / Virology 380 (2008) 285–295rov et al., 2001, 2005; Kraft et al., 2007; Letvin et al., 2001; Profy et al.,
1990; Vancott et al., 1995; Wu et al., 2006; Yang et al., 2004; Zolla-
Pazner, 2004; Zolla-Pazner et al., 2008). Early studies examined
vaccine sera against T-cell line adapted HIV-1 strains that were highly
sensitive to V3-mediated neutralization. Vaccine sera displayed
potent neutralization against prototype viruses such as MN, RF and
IIIB, but usually failed to neutralize primary virus strains that were not
adapted to growth in cell lines (Javaherian et al., 1990; Mascola et al.,Table 2
Neutralization by the indicated anti-V3 mAbs and GP vaccine sera against subtype C viruse
sCD4 IC80 μg/ml 447-52D 10 μg/ml 2219 10 μg/ml 3074 10
−sCD4 +sCD4 −sCD4 +sCD4 −sCD4
TV1.29 4.3 0% 100% 11% 87% 85%
Du156.12 200.0 0% 4% 0% 8% 0%
Du172.17 10.2 24% 31% 20% 24% 25%
Du422.1 100.0 16% 10% 17% 28% 1%
ZM197M.PB7 58.1 1% 0% 2% 11% 0%
ZM214M.PL15 160.0 24% 25% 9% 3% 0%
ZM233M.PB6 19.9 0% 6% 7% 43% 37%
ZM249M.PL1 43.9 4% 15% 10% 28% 0%
ZM53M.PB12 45.3 23% 10% 10% 9% 12%
ZM109F.PB4 2.5 17% 31% 45% 46% 75%
ZM135M.PL10a 83.5 44% 10% 36% 22% 33%
CAP45.2.00.G3 93.3 2% 12% 6% 25% 4%
CAP210.2.00.E8 22.7 0% 31% 0% 0% 13%
Breadth 0(0%) 1(8%) 0(0%) 1(8%) 2(15%
P-value 1 1 0.25
Values indicate percent neutralization when no sCD4 was present in the assay (-sCD4) and w
later value is the percent adjusted neutralization and indicates the effect of the mAb or GP se
the concentration of sCD4 required to inhibit viral entry by 80%. Note that the IC80 for sCD4w
mAb or GP sera was calculated using viral entry values at this level of sCD4 (e.g., Fig. 4). Va
breadth of neutralization. P-values were computed using the two-sided McNemar's test.1996; Monteﬁori et al., 1993; Spenlehauer et al., 1998; Wrin et al.,
1995; Wrin and Nunberg, 1994). In addition, V3-elicited antibodies
were often found to be highly strain speciﬁc, suggesting that the
antigenic diversity of the V3 loop posed a major obstacle for NAbs to
this variable region of Env (Lu, Putney, and Robinson, 1992; Nara et al.,
1990; Palker et al., 1988, 1998; Zwart et al., 1992). However, our
current understanding of the V3 domain suggests a signiﬁcant degree
of functional conservation, likely due to the interaction of V3 with thes with and without sCD4 present
μg/ml 83-2 1:10 86-2 1:10 86-6 1:10
+sCD4 −sCD4 +sCD4 −sCD4 +sCD4 −sCD4 +sCD4
96% 89% 95% 69% 95% 99% 99%
28% 85% 88% 25% 62% 41% 85%
66% 0% 6% 69% 85% 66% 79%
40% 1% 16% 8% 4% 0% 58%
8% 0% 0% 0% 16% 0% 59%
16% 0% 31% 0% 34% 0% 59%
58% 86% 87% 96% 97% 97% 97%
6% 0% 0% 0% 0% 0% 1%
54% 0% 0% 5% 26% 0% 89%
70% 56% 47% 84% 81% 87% 67%
31% 1% 0% 11% 0% 0% 0%
28% 0% 0% 0% 0% 7% 43%
41% 0% 22% 82% 76% 67% 69%
) 5(38%) 4(31%) 3(23%) 5(38%) 6(46%) 5(38%) 10(77%)
1 1 0.0625
ith sCD4 present (+sCD4) at a concentration sufﬁcient to inhibit viral entry by 80%. The
ra calculated based on baseline viral entry with sCD4 present. The second column shows
as derived separately for each virus and the percent adjusted neutralizationmediated by
lues greater than 50% neutralization are shown in bold and were used to calculate the
Fig. 5. In the presence of 5 μg/ml of sCD4, GP vaccine sera neutralized subtype C virus TV1.29 predominantly via anti-V3 antibodies. AV3 peptide (30 μg/ml) matched to the subtype C
vaccine immunogen was used to inhibit the V3-mediated neutralization by the sera. A scrambled V3 peptide had no inhibitory effect (not shown).
291X. Wu et al. / Virology 380 (2008) 285–295CCR5 or CXCR4 co-receptor prior to gp41-mediated viral fusion with
the target cell membrane (Cormier and Dragic, 2002; Huang et al.,
2005; Stanﬁeld et al., 2004, 2006). This functional conservation is
consistent with some level of antigenic conservation and the
observation that human anti-V3 mAbs can be reactive with the V3
loop of numerous strains of HIV-1 (Gorny et al., 2002, 2006; Gorny et
al., 1993; Krachmarov et al., 2005, 2006; Moore et al., 1995b). These
more broadly reactive human anti-V3 mAbs are able to neutralize a
subset of primary strains of HIV-1, but are ineffective against many
other HIV-1 isolates. This likely results because the V3 loop is
partially or completely inaccessible to antibody in the context of the
native structure of the trimeric gp120-gp41 complex (Binley et al.,
2004; Krachmarov et al., 2005; Lusso et al., 2005; Moore et al.,
1995a; Pantophlet et al., 2007; Pantophlet and Burton, 2006; Spen-
lehauer et al., 1998).
Env binding to CD4 induces a conformational stabilization of Env
that results in the formation of the co-receptor binding surface, as well
as movement of the V1V2 domain and exposure of the V3 loop.
Studies with soluble gp120 and Env expressed on the surface of
transfected cells have shown increased binding of co-receptor binding
site mAbs such as 17b and 48d, and anti-V3 mAbs after Env binds to
sCD4 (Krachmarov et al., 2006; Lusso et al., 2005; Mbah et al., 2001;
Salzwedel et al., 2000; Sullivan et al., 1998b; Wyatt and Sodroski,
1998; Xiang et al., 2002). These data suggested that sCD4-induced
exposure of the V3 loop could maximize V3-mediated neutralization
of free virus and would allow us to test whether the lack of anti-V3
neutralization of most viruses was due to poor recognition of the V3
loop or to limited accessibility of the epitope on native virus. ToFig. 6. Lack of effect of anti-CD4bs mAbs b12 and F105 on neutralization of JRFL by mAb 447-
of JRFL to anti-V3 antibodies, b12 and F105 did not affect neutralization sensitivity of JRFL to
the X-axes.address this question with representative viruses, we used panels of
well-characterized subtype B and C Env-pseudoviruses that were
derived during the acute phase of HIV-1 infection. We selected three
human anti-V3 mAbs, two derived from subtype B and one from a
CFR02-AG infected patient, and GP vaccine sera elicited by subtype B
or C Env immunogens that were known to contain moderate to high
levels of anti-V3 antibodies. Consistent with previous reports, the
anti-V3 mAbs and GP vaccine sera strongly neutralized several
prototype V3 sensitive viruses, but displayed more variable neutra-
lization against the subtype B and C reference viruses (Binley et al.,
2004; Li et al., 2005; Li et al., 2006; Wu et al., 2006; Yang et al., 2004).
However, upon pre-incubation with sCD4, 12 of 15 (80%) subtype B
viruses and 10 of 13 (77%) subtype C viruses were sensitive to V3-
mediated neutralization. These ﬁndings suggest that the V3 loop of
most HIV-1 isolates is recognized by anti-V3 mAbs and immune sera,
and that the low level of V3-mediated neutralization of many primary
virus strains is largely a result of inaccessibility of the V3 loop. The
level of accessibility of the V3 loop is in part dependent on the
antibody tested. For example, we found mAb 447-52D to have weak
neutralization activity against virus JRFL, but mAb B4e8, not tested
here, is reported to neutralize JRFL with an IC50 of 2.4 μg/ml.
(Pantophlet et al., 2007).
Of note, the amount of sCD4 required to trigger exposure of the V3
loop varied among viruses. Generally, concentrations of sCD4 that
inhibited viral entry by 50% to 80% were sufﬁcient to trigger exposure
of the V3 loop. For some viruses this required as little as 1 μg/ml of
sCD4 (e.g., JRFL), but the sCD4 IC80 value for other viruses was as high
as 200 μg/ml. As has been previously described, the CRF02_AG-52D and GP vaccine serum 82-4. Unlike sCD4, which increases neutralization sensitivity
anti-V3 antibodies. The IC50 and IC80 of sCD4, b12 and F105 against JRFL are indicated on
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ing activity than the subtype B-derivedmAbs 447-52D and 2219. Even
in the presence of sCD4, 447-52D and 2219 displayed little or no cross
neutralization against the subtype C viruses while 3074 neutralized
seven of 15 subtype B viruses. Therefore, a subtype AV3 sequence or a
consensus V3 sequence that is representative of multi-subtypes may
be a better immunogen than a subtype B V3 sequence. This is borne
out by our experience with subtype B and C Env immunogens. The
subtype C Env generated anti-V3 antibodies that cross-neutralized
sensitive subtype B viruses, whereas the anti-V3 response elicited by
the subtype B Envwas restricted to subtype B viruses (Wu et al., 2006).
Also, priming of immune responses with DNA from a subtype C Env
elicited a broader response than did priming with a subtype B Env
(Zolla-Pazner et al., 2008).
Overall, these data have implications for V3-based immunogen
design. In contrast to epitopes such as the membrane proximal
external region and the CD4bs of gp120, which appear to be poorly
immunogenic, anti-V3 antibodies can be elicited by current Env-based
vaccines. Such anti-V3 Abs display cross-subtype V3 reactivity, but do
not neutralize the majority of primary viruses and Env-pseudoviruses
against which they have been tested. If it were possible for an antibody
to induce conformation changes similar to those of sCD4, anti-V3
antibodies could play a major role in virus neutralization. To evaluate
this directly, we assayed two well-characterized anti-CD4bs mAbs to
determine if their binding to native virus resulted in exposure of the V3
loop. MAb b12 is the only CD4bs-directed mAb that can neutralize
most primary virus strains; mAb F105 neutralization is restricted to a
smaller subset of neutralization sensitive viruses. We chose virus JRFL
because its V3 loopwas highly exposed tomAb447-52Dneutralization
by incubation with relatively low concentrations of sCD4 (Fig. 1). Also,
JRFL is neutralized by both b12 and F105, although the former is much
more potent than the latter. Concentrations of either mAb sufﬁcient to
inhibit JRFL entry by 50% - 80% had no effect on 447-52D neutralization
of JRFL. This was perhaps expected for b12, which binds to the outer
domain of gp120 without causing signiﬁcant conformational rearran-
gements (Zhou et al., 2007). In contrast, thermodynamic and structural
data show that effective binding of sCD4 requires conformational
changes in gp120 (Kwong et al., 2002; Zhou et al., 2007). F105 also
induces moderate conformational rearrangement during binding to
gp120, but our data suggest that these do not result in full exposure of
the V3 loop to antibody. Whether the characteristic of sCD4 binding
that results in exposure of the V3 loop is unique to sCD4 remains to be
determined. Of note, numerous studies have suggested additive or
synergistic interactions betweenV3 antibodies and antibodies to other
regions of Env (Buchbinder et al., 1992; Cavacini et al., 1993; Laal et al.,
1994; Li et al., 1997; McKeating et al., 1992; Monteﬁori et al., 1993;
Moore and Sodroski,1996; Pinter, Honnen, and Tilley,1993; Potts et al.,
1993; Thali et al., 1992; Tilley et al., 1992; Vijh-Warrier et al., 1996). It
therefore remains possible that an antibody-mediated rearrangement
of Env conformation could lead to increased sensitivity to V3 loop
NAbs.
In summary, selected human anti-V3 mAbs and vaccine immune
sera can recognize the antigenic structure of V3 domain of the most
circulating subtype B and C virus strains, but the V3 loop is often
masked, or partially masked, in the context of the native viral spike.
Vaccine elicited anti-V3 antibodies may have enough potency to
neutralize a subset of V3 sensitive primary viruses, but this antibody
speciﬁcity will likely need to be augmented by NAbs against other
viral epitopes for an antibody-based vaccine to be effective.
Materials and methods
Antibodies, cells and virus stocks
The anti-V3 mAbs 447-52D, 2219 and 3074 were described
previously (Conley et al., 1994; Gorny et al., 1992, 2002, 2006; Nyambiet al., 1998). The co-receptor binding site antibody 17b was obtained
from James Robinson (Tulane University). The CD4bs mAbs b12 was
provided by Dennis Burton and Ralph Pantophlet (Scripps Research
Institute); F105 was from the laboratory of Marshall Posner (Dana-
Farber Cancer Institute). Two domain sCD4 (sCD4-183) was obtained
through the NIH AIDS Research and Reference Reagent Program and
from Pharmacia. Human embryonic kidney cell line 293T was pur-
chased from the American Type Culture Collection and maintained in
DMEM (Gibco, Invitrogen, Carlsbad, CA) containing 10% heat-inacti-
vated fetal bovine serum and 100 μg/ml of penicillin/streptomycin.
The TZM-bl cells were obtained from the NIH AIDS Research and
Reference Reagent Program, as contributed by John Kappes and
Xiaoyun Wu. This cell line is a genetically engineered HeLa cell clone
that expresses CD4, CXCR4, and CCR5, and contains HIV Tat-respon-
sive reporter genes for ﬁreﬂy luciferase and Escherichia coli β-galac-
tosidase under regulatory control of an HIV-1 long terminal repeat.
Pseudovirus was prepared by transfecting 293T cells (6×106 cells
in 50 ml growth medium in a T-175 culture ﬂask) with 10 μg of rev/env
expression plasmid and 30 μg of an env-deﬁcient HIV-1 backbone
vector (pSG3ΔEnvelope), using Fugene 6 transfection reagents (Roche,
Nutley, NJ). Pseudovirus-containing culture supernatants were har-
vested 2 days after transfection, ﬁltered (0.45 μm), and stored at –80°C
or in the vapor phase of liquid nitrogen. The virus 50% tissue culture
infectious dose (TCID50) was determined on TZM-bl cells by serial 5-
fold dilutions of the pseudovirus stock in quadruplicate wells. At
approximately 48 h, the infection levels were determined by a
luciferase assay (Bright Glo, Promega, Madison, WI) using the cell
lysate. Infections producing the RLU three times above the mock
infection background were scored as positive.
Constructions of plasmid DNA, recombinant adenoviruses and
vaccination
The construction of plasmid DNA and rAd5 were described
previously (Wu et al., 2006). Selective modiﬁcations of the HIV-1
Env included ΔCFI, indicating deletions in the cleavage site, fusogenic
domain, and spacing of heptad repeat 1 and 2, and ΔV1V2(V3-1AB),
indicating deletions of the V1V2 loop and two small deletions on both
arms of the V3 stem (Chakrabarti et al., 2002, 2005; Wu et al., 2006;
Yang et al., 2004). HIV-1 env genes encoding BaL gp145ΔCFI, and Hx/
BaL gp145ΔCFI were synthesized using human-preferred codons as
previously described. In gp145ΔCFIΔV1V2 (ZA012V3-1AB), amino
acids 202–388 of BaL V3 were replaced by amino acids 195–382 of
subtype C ZA012 V3 sequence.
GP immunizations were performed as previously descried (Wu et
al., 2006). Brieﬂy, animals were immunized intramuscularly with
500 μg (in 400 μl PBS) of the gp145 version of plasmid DNA at weeks 0,
2 and 6. At week 14, GPs were boosted with 1011 particles (in 400 μl
PBS) of rAd5 expressing the corresponding gp140 version of the HIV-1
Env protein. Serum tested in this study was collected 2weeks after the
rAd5 boost immunization. GP group 82 received a subtype B V3 in a
subtype B Env backbone (BaL gp145 ΔCFI ΔV1V2 (V3-1AB)); groups 83
and 86 received a subtype C V3 (ZA012V3-1AB) in a subtype B Env
backbone. This backbonewas BaL gp145 ΔCFI ΔV1V2 for group 83 and
Hx/BaL gp145 ΔCFI ΔV1V2 for group 86.
Neutralization and V3 peptide competition assays
Neutralization was measured using HIV-1 Env-pseudoviruses to
infect TZM-bl cells as described previously (Li et al., 2005; Shu et al.,
2007). Brieﬂy, 40 μl of virus was incubated for 30 min at 37 °C with
10 μl of serial dilutions of test antibody or serum samples in duplicate
wells of a 96-well ﬂat bottom culture plate. For neutralization assays
with sCD4, 5 μl of sCD4 was added to the virus for 30 min followed by
addition of 5 μl of test mAb or serum sample. To keep assay
conditions constant, sham media was used in place of sCD4 or
293X. Wu et al. / Virology 380 (2008) 285–295antibody in speciﬁed control wells. The mAb and sCD4 concentra-
tions, and serum dilutions, were deﬁned at the point of incubation
with virus supernatant. 10,000 TZM-bl cells were then added to each
well in a volume of 20 μl, and plates were incubated overnight at
37 °C in a 5% CO2 incubator. One set of eight wells received mock
antibody followed by virus and cells as controls for virus entry, and a
set of eight wells received cells with mock virus to control for luci-
ferase background. After overnight incubation, 150 μl of fresh
medium was added to each well. Infection levels were determined
the next day using a quantitative luciferase assay measuring
luciferase activity present in cell lysate (Promega). The virus input
was set at a multiplicity of infection (Ortiz et al., 1999) of appro-
ximately 0.1, which generally results in 100,000 to 400,000 RLU in
the luciferase assay. Neutralization curves were ﬁt by non-linear
regression using a 4-parameter hill slope equation programmed into
JMP statistical software (JMP 5.1, SAS Institute Inc., Cary, NC). The 50%
or 80% inhibitory concentrations (IC50 and IC80) are reported as the
reciprocal serum dilutions or mAb concentrations required to inhibit
infection by 50% or 80%.
The V3 peptide competition assays were done in the same assay
format as the neutralization assay, except that the control or test
peptide was added to antibody or serum 30 min prior to the addition
of virus. The concentration of peptide used was 30 μg/ml, and
represents the concentration that was present whenpeptide, serum or
antibody and virus were incubated together. The V3 peptide
sequences used in this study were based either on BaL.26
(TRPNNNTRKSIHIGPGRAFYTTG) or ZA012 (TRPNNNTRKSMRIGPGQT-
FYATG), each matching the representative vaccine strain. A scrambled
V3 peptide (IGPGRATRPNNNFYTTGTRKSIH) was used as a negative
control. These peptides were synthesized by SynPep (Dublin, CA).
Statistical analysis
Comparisons of neutralization breadth in the absence and presence
of sCD4 were performed by McNemar's test using the statistical
packagewithin R software. Comparisons of neutralization values in the
absence and presence of sCD4 were performed by paired Wilcoxon
signed-rank test using the statistical package within GraphPad Prism
(V5.0) software. P-values≤0.05 are reported as signiﬁcant.
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